PharmaEssentia Management
Management criteria checks 3/4
PharmaEssentia's CEO is Ko-Chung Lin, appointed in Jan 2017, has a tenure of 7.33 years. directly owns 1.62% of the company’s shares, worth $58.81M. The average tenure of the management team and the board of directors is 4.6 years and 4.5 years respectively.
Key information
Ko-Chung Lin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.3yrs |
| CEO ownership | 1.6% |
| Management average tenure | 4.6yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | NT$442m |
| Dec 31 2023 | n/a | n/a | -NT$624m |
| Sep 30 2023 | n/a | n/a | -NT$890m |
| Jun 30 2023 | n/a | n/a | -NT$1b |
| Mar 31 2023 | n/a | n/a | -NT$2b |
| Dec 31 2022 | n/a | n/a | -NT$1b |
| Sep 30 2022 | n/a | n/a | -NT$2b |
| Jun 30 2022 | n/a | n/a | -NT$2b |
| Mar 31 2022 | n/a | n/a | -NT$3b |
| Dec 31 2021 | NT$9m | NT$9m | -NT$3b |
| Sep 30 2021 | n/a | n/a | -NT$3b |
| Jun 30 2021 | n/a | n/a | -NT$3b |
| Mar 31 2021 | n/a | n/a | -NT$2b |
| Dec 31 2020 | NT$9m | NT$9m | -NT$2b |
| Sep 30 2020 | n/a | n/a | -NT$1b |
| Jun 30 2020 | n/a | n/a | -NT$862m |
| Mar 31 2020 | n/a | n/a | -NT$856m |
| Dec 31 2019 | NT$9m | NT$8m | -NT$843m |
Compensation vs Market: Insufficient data to establish whether Ko-Chung's total compensation is reasonable compared to companies of similar size in the Luxembourg market.
Compensation vs Earnings: Ko-Chung's compensation has been consistent with company performance over the past year.
CEO
Ko-Chung Lin
7.3yrs
Tenure
NT$9,389,000
Compensation
Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | 11.7yrs | NT$8.49m | 1.02% NT$ 37.1m | |
| Founder | 7.3yrs | NT$9.39m | 1.62% NT$ 58.8m | |
| President | no data | NT$8.49m | 0.61% NT$ 22.1m | |
| Accounting Manager & Senior Manager of Finance | 8.6yrs | no data | no data | |
| VP and Head of Business Operations & Strategy | 2.3yrs | no data | no data | |
| Chief Scientific Officer | 1.8yrs | no data | 0.020% NT$ 712.5k | |
| VP and Head of Corporate Communications & Advocacy | 2.3yrs | no data | no data | |
| Senior VP and Head of Sales & Marketing | 3.3yrs | no data | no data | |
| Senior VP & Head of People | 2.3yrs | no data | no data | |
| Chief Medical Officer | 7.3yrs | no data | 0.022% NT$ 803.2k | |
| Head of Japan Medical Affairs | 5.8yrs | no data | no data | |
| Chief Operating Officer of Taichung Plant | 5.8yrs | no data | no data |
4.6yrs
Average Tenure
Experienced Management: 261280558's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | 11.7yrs | NT$8.49m | 1.02% NT$ 37.1m | |
| Founder | 2.8yrs | NT$9.39m | 1.62% NT$ 58.8m | |
| President | 9yrs | NT$8.49m | 0.61% NT$ 22.1m | |
| Independent Director | 10.2yrs | NT$75.00k | no data | |
| Independent Director | 10.2yrs | NT$120.00k | 0.029% NT$ 1.0m | |
| Director | 17.9yrs | NT$120.00k | 0.72% NT$ 26.3m | |
| Independent Director | 5.9yrs | NT$120.00k | 0.00060% NT$ 21.8k | |
| Chairperson of Japan | 3yrs | no data | no data | |
| Director | 2.8yrs | NT$95.00k | no data | |
| Director | 2.8yrs | NT$95.00k | 0.25% NT$ 9.0m | |
| Director | 2.8yrs | NT$95.00k | 0.0032% NT$ 114.6k | |
| Director | 1.3yrs | no data | no data |
4.5yrs
Average Tenure
Experienced Board: 261280558's board of directors are considered experienced (4.5 years average tenure).